TITLE

NIH FUNDS CLINICAL DEVELOPMENT OF VIVAGEL FOR GENITAL HERPES

PUB. DATE
June 2006
SOURCE
Worldwide Biotech;Jun2006, Vol. 18 Issue 6, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the funding agreement established between Starpharma Holdings Ltd. of Melbourne, Victoria and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Plan by NIAID to fund a clinical trial to test the use of VivaGelâ„¢ in the prevention of genital herpes; Implications of the funding agreement for Starpharma; Prevalence of genital herpes in the U.S.
ACCESSION #
20929255

 

Related Articles

  • AIDS Clinical Trials Group (ACTG):. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p14 

    The article presents an encyclopedia entry about the AIDS Clinical Trials Group. This is the trial network for the AIDS drugs of the National Institute of Allergy and Infectious Diseases. The National Institute of Allergy and Infectious Diseases coordinates with various institutions in order to...

  • Breakthrough of the Year.  // BioSpectrum;Jan2012, Vol. 10 Issue 1, p97 

    The article announces that the HPTN 052 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) has received the 2011 Breakthrough of the Year award.

  • Optimizing the clinical identification and management of patients at risk for anaphylaxis. Stoloff, Stuart W. // Journal of Family Practice;Aug2010 Supplement 1, Vol. 59, pS1 

    The August 2010 issue of "The Journal of Family Practice" which focuses on the optimization of clinical identification and management of patients at risk for anaphylaxis is presented. It notes the definition of anaphylaxis by the National Institute of Allergy and Infectious Diseases in the U.S....

  • Enrollment of Racial/Ethnic Minorities in NIAID-Funded Networks of HIV Vaccine Trials in the United States, 1988 to 2002. Djomand, Gaston; Katzman, Joanna; DiTommaso, Dante; Hudgens, Michael G.; Counts, George W.; Koblin, Beryl A.; Sullivan, Patrick S. // Public Health Reports;Sep/Oct2005, Vol. 120 Issue 5, p543 

    Objective. The purpose of this study was to analyze enrollment of racial/ethnic minorities in Phase I and Phase II HIV vaccine trials in the U.S. conducted by National Institute of Allergy and Infectious Diseases (NIAID)-funded networks from 1988 to 2002. Methods. A centralized database was...

  • Understanding the P5 Partnership. McEnery, Regina // VAX; 

    The article offers information on a global coalition of researchers who have been trying to identify the immune responses provoked by the RV144 regimen, a clinical trial that established that a vaccine can prevent HIV infection. It is informed that the coalition is known as the Pox-Protein...

  • Developing a conceptual framework for an evaluation system for the NIAID HIV/AIDS clinical trials networks. Kagan, Jonathan M.; Kane, Mary; Quinlan, Kathleen M.; Rosas, Scott; Trochim, William M. K. // Health Research Policy & Systems;2009, Vol. 7, p1 

    Globally, health research organizations are called upon to re-examine their policies and practices to more efficiently and effectively address current scientific and social needs, as well as increasing public demands for accountability.Through a case study approach, the authors examine an effort...

  • XOMA Wins $65M Contract for Botulism Therapeutic.  // BioWorld Today;9/10/2008, Vol. 19 Issue 176, p2 

    This article announces that the National Institute of Allergy and Infectious Diseases has awarded XOMA Ltd. a $65 million contract in September 2008, to develop drugs for the management of botulism poisoning. As stated, Berkeley, California-based XOMA intends to conduct efficacy and safety tests...

  • NIAID Looks for Next HIV PrEP. Serebrov, Mari // BioWorld Today;7/20/2012, Vol. 23 Issue 140, p5 

    The article reports on a clinical trial, to be carried out by ViiV Healthcare Ltd. and to be funded by the National Institute of Allergy and Infectious Diseases (NIAID), for HIV drug Selzentry as a possible pre-exposure prophylaxis (PrEP).

  • Vaxonco Starts Phase I Trial of Malaria Vaccine EPI300. Moran, Nuala // BioWorld International;9/29/2010, Vol. 15 Issue 38, p1 

    The article reports that South Korean vaccines specialist Vaxonco Inc. has started a Phase I trial of EPI300, a multiple epitope vaccine against malaria. Funded by the U.S. National Institute of Allergy and Infectious Diseases, the trial will evaluate the safety and immunogenicity in 39...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics